1. Introduction {#sec1}
===============

Serum uric acid is the final enzymatic product of purine metabolism \[[@B1], [@B2]\]. Abnormalities in serum uric acid metabolism may cause hyperuricemia and gout. Hyperuricemia is the result of interactions among multiple factors, including sex, age, genetics, lifestyle, and environment \[[@B3]\]. Several studies have suggested that hyperuricemia is associated with many diseases, including diabetes mellitus \[[@B4]\], hypertension \[[@B5], [@B6]\], stroke \[[@B2], [@B7]\], dyslipidemia \[[@B8]\], chronic kidney disease \[[@B9]\], cardiovascular events, and heart failure \[[@B10]--[@B12]\]. Hyperuricemia is considered to be a precursor of gout as the deposition of urate crystals in the joints results in an acute inflammatory response. Deposition in the soft tissue can lead to tophi \[[@B13]--[@B15]\]. Gout is also a serious health issue and is an independent risk factor for heart failure and metabolic syndrome \[[@B16], [@B17]\]. In recent years, an increasing trend in the prevalence of hyperuricemia and gout has been observed in epidemiological studies \[[@B13], [@B18]--[@B21]\], and both diseases have become public health problems that need to be solved quickly.

Due to rapid economic development, the lifestyle of the Chinese has changed greatly, a huge transition from a dietary pattern traditionally based on carbohydrates and vegetables to a pattern that relies on meat, dairy products, and other purine-rich foods that are closely related to hyperuricemia and gout \[[@B22], [@B23]\].

As a large developing country, China has marked regional differences and varied populations. To date, most investigations have been limited to certain areas or have focused on specific occupations. Therefore, a comprehensive study on the epidemiology of hyperuricemia and gout in the entire mainland China is needed. As most of the published data are in Chinese, we present our study in the widely read English medium. Obtaining an accurate prevalence of hyperuricemia and gout is important to help us formulate appropriate local public health policies. In addition, such a study will benefit the people through health education by increasing awareness of hyperuricemia and gout and also the importance of improving lifestyle and maintaining a healthy diet.

Due to varied geographic locations that include diverse populations and different socioeconomic conditions, a unified epidemiological investigation about the prevalence of hyperuricemia and gout remains difficult. We conducted a meta-analysis regarding the prevalence of both diseases in mainland China between January 2000 and December 2014 to determine the epidemiology and to review the results from previous studies.

2. Methods {#sec2}
==========

2.1. Search Strategy {#sec2.1}
--------------------

We manually searched all of the literatures regarding population-based research on the prevalence of hyperuricemia and gout from 2000 to 2014 using the PubMed, Google Scholar, CNKI (Chinese National Knowledge Infrastructure), Chinese Wangfang, and Chongqing VIP electronic databases. The keywords for search were "uric acid," "HUA," "HU," "hyperuricemia," "gout," "prevalence(s)," "incidence(s)," and "epidemiology." To find additional studies, the reference lists of the identified studies were also examined.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

Papers were included if they met all of the following criteria: (1) all study participants living in mainland China; (2) study data being general population-based rather than hospital-based; (3) prevalence rate being also analyzed by according to sex; (4) accurate diagnostic criteria and clear study date; and (5) the most detailed study of duplicate studies on the same population.

Studies were excluded if they (1) were not original research, such as a review or case report, (2) included participants with concomitant diseases or had medication history known to affect uric acid metabolism, or (3) focused on specific population groups, such as teenagers, elderly people, or single gender, or a certain occupation.

2.3. Definition of Hyperuricemia and Gout {#sec2.3}
-----------------------------------------

The diagnostic criteria for hyperuricemia varied among the studies; we have listed each criterion in [Table 1](#tab1){ref-type="table"}. The diagnostic criteria for gout were listed in [Table 2](#tab2){ref-type="table"} \[[@B24], [@B25]\].

2.4. Data Extraction {#sec2.4}
--------------------

Two reviewers searched the literature independently. Any disagreement on data extraction between the two reviewers was mediated by discussion \[[@B26]\]. [Figure 1](#fig1){ref-type="fig"} shows the literature-search process. We recorded the characteristics of all the included papers in [Table 1](#tab1){ref-type="table"}, including the title, author\'s name, publication date, study year, study population, geographic area, rural/urban, inland/coastal, sample size, case, prevalence, and diagnostic criterion.

2.5. Statistical Analysis {#sec2.5}
-------------------------

Pooled prevalence and 95% confidence intervals (CIs) were calculated to estimate the prevalence of hyperuricemia and gout in mainland China. We adopted the Chi-squared-based *Q* test and the *I* ^2^ test to evaluate the heterogeneity of the studies; 25%, 50%, and 75% were considered low, moderate, and high levels, respectively \[[@B27], [@B28]\]. If the level of heterogeneity was moderate or high, we used a random-effects meta-analysis model instead of a fixed-effects model. To perform a secondary analysis and to address heterogeneity, a subgroup analysis was required. Egger\'s test was used to estimate publication bias. A *P* value less than 0.05 was considered statistically significant. Meta-analysis was calculated using Stata Version 11.0 (Stata Corp LP, College Station, TX, USA). Significant differences in prevalence among the groups were examined through the Chi-square test using SPSS Version 20.0 (SPSS Software, Chicago, IL, USA). All figures were generated using Stata 11.0 (Stata Corp LP, College Station, TX, USA) or Microsoft PowerPoint (Microsoft, Redmond, USA).

3. Results {#sec3}
==========

3.1. Characteristics of Included Studies {#sec3.1}
----------------------------------------

A total of 604 articles were identified ([Figure 1](#fig1){ref-type="fig"}). After screening for population base, study type, relevancy, and duplicates, 36 literary papers (3 in English and 33 in Chinese) containing 44 studies (38 regarding hyperuricemia and 6 regarding gout) met our inclusion criteria. A detailed description of these studies is provided in [Table 1](#tab1){ref-type="table"}.

3.2. Pooled Prevalence of Hyperuricemia and Gout {#sec3.2}
------------------------------------------------

As shown in [Figure 2](#fig2){ref-type="fig"}, the pooled prevalence of hyperuricemia was 13.3% (95% CI: 11.9%, 14.6%), with the prevalence ranging from 5.5% to 23.6%. As shown in [Figure 3](#fig3){ref-type="fig"}, the pooled prevalence of gout was 1.1% (95% CI: 0.7%, 1.5%), with a range of 0.4--1.5%.

Figures [4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"} showed the individual prevalence of hyperuricemia and gout, respectively, in different provinces, municipalities, and autonomous regions.

3.3. Subgroup Analysis {#sec3.3}
----------------------

The prevalence of hyperuricemia in mainland China was analyzed in subgroups, which were separated based on the following categories: rural or urban, coast or inland, location (north, south, northwest, northeast, and southwest China), economic level, and sex. As shown in [Table 3](#tab3){ref-type="table"}, location in an urban area (*χ* ^2^ = 25.53, *P* \< 0.001), inland area (*χ* ^2^ = 117.95, *P* \< 0.001), or south China (*χ* ^2^ = 507.39, *P* \< 0.001) and a high economic level (*χ* ^2^ = 8.40, *P* = 0.004) might indicate a high prevalence of hyperuricemia. Notably, sex may also be closely associated with hyperuricemia prevalence, as the prevalence among men and women was 19.4% (95% CI: 17.6%, 21.1%) and 7.9% (95% CI: 6.6%, 9.3%), respectively.

For gout, the prevalence among the subgroups was very different ([Table 4](#tab4){ref-type="table"}). Urban residents had a much higher prevalence of gout (1.2%, 95% CI: 0.7%, 1.8%) compared with rural residents (0.9%, 95% CI: 0.2%, 1.6%; *χ* ^2^ = 19.96, *P* \< 0.001). Inland area residents had a higher prevalence of gout (1.4%, 95% CI: 0.8%, 1.9%) than coastal area residents (0.8%, 95% CI: 0.2%, 1.4%; *χ* ^2^ = 23.88, *P* \< 0.001). An increasing prevalence of gout was seen over the years; 0.9% (95% CI: 0.0%, 1.8%) of subjects investigated from 2000 to 2005 were diagnosed with gout, and this number increased to 1.4% (95% CI: 0.5%, 2.2%) after 2010 (*χ* ^2^ = 7.47, *P* = 0.024). Regarding sex, the prevalence rate was 1.5% (95% CI: 0.8%, 2.1%) in men and 0.9% (95% CI: 0.0%, 1.0%) in women.

3.4. Analysis of Heterogeneity and Publication Bias {#sec3.4}
---------------------------------------------------

A significant overall heterogeneity was noted in the study on hyperuricemia (*P* \< 0.001, *I* ^2^ = 98%); however, the heterogeneity decreased in the subgroup analysis. We observed publication bias in both studies according to Egger\'s test. Then we performed a trim and fill method to address the problem of publication bias. However, it became unchanged after we applied the trim and fill method \[[@B65]\].

4. Discussion {#sec4}
=============

We analyzed 44 epidemiological surveys covering 16 provinces, municipalities, and autonomous regions in mainland China. An important strength of our study is that it is a cross-sectional study. We systematically analyzed the prevalence of hyperuricemia and gout in mainland China. To our knowledge, this is the first study of this kind to focus on mainland China and cover the years from 2000 to 2014.

In our meta-analysis, the prevalence of hyperuricemia in mainland China was 13.3% (19.4% in men and 7.9% in women), which was in accordance with the worldwide prevalence rate reported to be ranging from 2.6% to 36% in different populations \[[@B66]\]. Our result was lower than that observed in several developed countries, such as the United States (21.2% in men and 21.6% in women) \[[@B21]\] and Japan (25.8% overall, 34.5% in men and 11.6% in women) \[[@B67]\]. As expected, the prevalence is close to that in most developing countries; for example, it is 10.6% in Thailand (18.4% in men and 7.8% in women) \[[@B68]\] and 12.1% in Turkey (19.0% in men and 5.8% in women) \[[@B69]\]. Chuang et al. performed the Nutrition and Health Survey in Taiwan (NAHSIT) study from 2005 to 2008, which focused on a Chinese population, but the results of their study differed significantly from those of our study. In their reports the prevalence of hyperuricemia was 21.6% in men and 9.6% in women \[[@B70]\], which was higher than ours and similar to that in developed countries. Our research was performed on mainland China, whereas Chuang\'s study was conducted in Taiwan, an economically-developed region in China. We believe that our results are more representative of the Chinese population living in the mainland.

As China is geographically vast, the prevalence of hyperuricemia varies significantly in different geographic regions. The prevalence in south China was 18.6%, which is much higher than the pooled prevalence, followed by southwest China (13.9%), north China (13.2%), east China (12.9%), northwest China (10.3%), and northeast China (10.1%). Such differences might be related to variability in lifestyle and economic development. As a previous study described, rapidly increasing economic development has led to unhealthy lifestyles \[[@B71]\]. Residents in south China, which is an economically developed region, consume more meat, seafood, and alcohol than residents elsewhere; therefore, the prevalence of hyperuricemia was higher in south China than in other regions. Also, hyperuricemia was more common in urban residents than in rural residents, and the inland prevalence of hyperuricemia was much higher than in coastal areas.

From our study, the pooled prevalence of gout was 1.1%, which is similar to that in Italy (0.9% in 2009) \[[@B19]\], France (0.9% in 2013) \[[@B72]\], the United Kingdom, and Germany (1.4% in 2000--2005) \[[@B17]\]. In addition, the prevalence of gout in our country was much higher than that in Turkey (0.31% in 2001-2002) \[[@B74]\], Mexico (0.3% in 2011) \[[@B75]\], Greece (0.47% in 2003) \[[@B76]\], and the Czech Republic (0.3% in 2002-2003) \[[@B77]\] but is markedly lower than that in New Zealand (2.69% in 2008-2009) \[[@B78]\], the USA (3.9% in 2007-2008) \[[@B21]\], and Australia (9.7% in 2002) \[[@B79]\].

Another main finding in our study was that the prevalence of gout in men (1.5%) was remarkably higher than in women (0.9%). This difference in sex was consistent with previous studies in other populations. Soriano et al. investigated the current epidemiology of gout in the general United Kingdom population and suggested that the incidence of gout was 4.42 per 1,000 persons per year in men and 1.32 per 1,000 persons per year in women \[[@B13]\]. Zhu et al. reported that the prevalence in the US was 5.9% in men, which was much higher than the 2.0% observed for women \[[@B21]\]. In accordance with these researches, prevalence of gout in Taiwan was 9.2% for men and 2.3% for women \[[@B70]\]. Sex hormones may explain the difference between the sexes. Ghei et al. suggested that the serum uric acid levels were higher in men than in women and that this difference is under the influence of sex hormones. Uric acid levels in women tend to increase after menopause \[[@B69], [@B80]\].

Moreover, in line with previous results, a rise in the prevalence of gout was observed in the current study. The prevalence was 0.9% in 2000--2005, 1.1% in 2006--2010, and 1.4% in 2011--2014. The US National Health and Nutrition Examination Survey (NHANES) study conducted in 2007-2008 demonstrated that the prevalence of gout was 3.9%, though it was only 2.7% in 1988--1994 \[[@B21]\]. The NAHSIT studies, carried out during 1993--1996 and 2005--2008, showed that the prevalence of gout increased from 4.7% to 8.2% in men and 2.2% to 2.3% in women \[[@B70]\]. To help reduce the increasing burden of these diseases, prospective data on modifiable risk factors in lifestyle and diet for these conditions should be considered including, but not limited to, weight control, regular exercise, restricted intake of meat and purine-rich foods, and avoidance of heavy drinking. Vitamin C supplementation may also be considered a long-term preventive measure as it can lower the risk of gout through lowering serum urate levels \[[@B81], [@B82]\].

Noteworthy, there is a lack of unified diagnostic criteria for gout, and several sets of criteria exist, such as the Rome criteria, the New York criteria, and the American Rheumatology Association (ARA) criteria \[[@B24]\]. The gold standard to diagnose gout is the presence of monosodium urate monohydrate (MSU) crystals in the synovial fluid (SF) at the time the patient experiences a gout attack \[[@B83]\]. The sets of criteria that include MSU crystals in SF have high specificity, and the exclusion of MSU crystal examination has led to a dramatic reduction in sensitivity \[[@B84]\]. However, MSU crystal examination is not always feasible in clinical practice. In 2015, Taylor et al. performed the Study for Updated Gout Classification Criteria (SUGAR) and determined ten parameters for accurately distinguishing gout from nongout \[[@B85]\]. In the same year, the American College of Rheumatology developed a new classification criteria for gout \[[@B86]\]. All the studies included in our analysis were performed from 2000 to 2014; therefore they were unable to adopt the new classification criteria. The diagnostic criteria used in this study could lead to a possible high sensitivity but low specificity. Because of this, the prevalence of gout in our analysis may be slightly higher than the actual rate, but it represents the general prevalence of gout and its geographical distribution in China.

Our meta-analysis has several other limitations. First, the pooled data covered only part of mainland China, especially for gout; however, our data did cover 16 provinces, municipalities, and autonomous regions. To our knowledge, it is the most encompassing cross-sectional study on hyperuricemia and gout prevalence in China. Second, the primary studies on hyperuricemia used different assays to assess serum uric acid levels with different reference intervals. Third, there were variations in the quality of the selected articles; hence heterogeneity may be influenced by uncertain data. Fourth, as much concern is given to this topic by Chinese doctors, the majority of the studies included were published in Chinese. However, this limitation was overcome by the current authors who are proficient in Chinese for interpretation and extraction of data. Also, sample size of included papers was too small in our subgroup analysis for the prevalence of gout, so there was no statistical power to explore the association between gout prevalence and geographic regions. Our work underlines the need for additional population-based investigations in the areas absent from our analysis. This is the first study to assess the nationwide epidemiology of hyperuricemia and gout in mainland China.

In conclusion, as previous studies were limited to specific regions, our study on the epidemiology of hyperuricemia and gout is of value to public health policies. Based on previous studies, we show that the prevalence of these diseases is high and that the rate of gout is rising. Consequently, large well-designed multicenter investigations are required in the future to provide information regarding the outcomes and prognosis of these chronic diseases in the entire population. Furthermore, effective measures should be adopted to prevent the increase in incidence of these diseases.
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###### 

Characteristics of studies on the prevalence of hyperuricemia and gout.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author                  Publication year   Area                   Diagnostic criterion (*μ*mol/L)  \   Rural/urban   Inland/coastal   Study year   Sample size   Case   Prevalence (%)
                                                                          (Men/Women)                                                                                           
  ----------------------------- ------------------ ---------------------- ------------------------------------ ------------- ---------------- ------------ ------------- ------ ----------------
  Prevalence of hyperuricemia                                                                                                                                                   

  Shi \[[@B29]\]                2013               Shijingshan, Beijing   ≥420/≥350                            Urban         Inland           2012         3961          438    11.06

  Ma \[[@B30]\]                 2014               Xichengqu, Beijing     ≥417/≥357                            Urban         Inland           2012         834           100    11.99

  Li \[[@B31]\]                 2013               Bortala, Xinjiang      \>420/\>350                          Rural         Inland           2009         2046          261    12.76

  Zheng \[[@B32]\]              2010               Wenzhou, Zhejiang      ≥417/≥357                            Urban         Inland           2008         1520          114    7.50

  Sun \[[@B33]\]                2008               Dalian, Liaoning       ≥420/≥350                            Rural         Coastal          2007         1024          100    9.77

  Hou \[[@B34]\]                2010               Dalian, Liaoning       \>420/\>350                          Rural         Coastal          2007         1021          97     9.50

  Wang \[[@B35]\]               2010               Baoshan, Yunnan        \>420/\>350                          Urban         Coastal          2009         1501          210    13.99

  Yu \[[@B36]\]                 2010               Foshan, Guangdong      ≥417/≥357                            Urban         Coastal          2008         7403          1117   15.09

  Wu \[[@B37]\]                 2008               Guangzhou, Guangdong   ≥417/≥357                            Urban         Inland           2007         2788          578    20.73

  Zou \[[@B38]\]                2011               Guilin, Guangxi        ≥420/≥360                            Urban         Inland           2009         6273          1477   23.55

  Wang \[[@B39]\]               2008               Zhoushan, Zhejiang     \>420/\>360                          Rural         Inland           2007         1438          158    10.99

  Meng \[[@B40]\]               2012               Gaoyou, Jiangsu        ≥420/≥360                            Rural         Inland           2010         4504          538    11.94

  Shen \[[@B41]\]               2014               Wuxi, Jiangsu          ≥417/≥357                            Urban         Inland           2009         3723          754    20.25

  Song \[[@B42]\]               2014               Nanchang, Jiangxi      \>420/\>350                          Urban         Inland           2011         3795          795    20.95

  Shao \[[@B43]\]               2003               Nanjing, Jiangsu       ≥417/≥357                            Urban         Inland           2003         7778          1038   13.35

  Zhou \[[@B44]\]               2013               Ningbo, Zhejiang       \>420/\>370                          Urban         Coastal          2008         2110          190    9.00

  Huang \[[@B45]\]              2013               Ningbo, Zhejiang       \>420/\>360                          Urban         Coastal          2012         1754          195    11.12

  Xin \[[@B46]\]                2013               Qingdao, Shandong      \>420/\>350                          Urban         Coastal          2011         5165          748    14.48

  Tian \[[@B47]\]               2008               Qingdao, Shandong      \>420/\>350                          Urban         Coastal          2006         2363          471    19.93

  Tian \[[@B47]\]               2008               Qingdao, Shandong      \>420/\>350                          Rural         Coastal          2006         2467          405    16.42

  Dong \[[@B48]\]               2004               Qingdao, Shandong      \>420/\>350                          Urban         Coastal          2002         2190          402    18.36

  Zhang \[[@B49]\]              2006               Haiyang, Shandong      \>416.36/\>356.88                    Rural         Coastal          2004         5372          649    12.08

  Wang \[[@B50]\]               2010               Shenyang, Liaoning     \>420/\>350                          Urban         Inland           2009         675           78     11.56

  Chen \[[@B51]\]               2008               Chengdu, Sichuan       ≥428                                 Urban         Inland           2006         2566          400    15.59

  Guo \[[@B52]\]                2012               Taiyuan, Shanxi        ≥420                                 Urban         Inland           2010         4228          371    8.77

  Wang \[[@B53]\]               2010               Wenzhou, Zhejiang      \>420/\>350                          Urban         Coastal          2008         3478          260    7.48

  Shao \[[@B54]\]               2011               Wenzhou, Zhejiang      \>420/\>350                          Urban         Coastal          2008         3480          260    7.47

  Pan \[[@B55]\]                2014               Changzhou, Jiangsu     \>420/\>380                          Rural         Inland           2008         3122          573    18.35

  Duan \[[@B56]\]               2013               Korla, Xinjiang        \>417/\>357                          Urban         Inland           2009         2046          261    12.76

  Zhang \[[@B57]\]              2014               Xingtai, Hebei         \>420/\>350                          Rural         Inland           2013         2109          177    8.39

  Mou \[[@B58]\]                2013               Yantai, Shandong       ≥380                                 Urban         Coastal          2012         635           66     10.39

  Li \[[@B59]\]                 2010               Yan\'an, Shaanxi       \>417/\>357                          Urban         Inland           2008         1290          71     5.50

  Chen \[[@B60]\]               2009               Dali, Yunnan           \>420/\>350                          Urban         Inland           2006         7505          923    12.30

  Jin \[[@B61]\]                2009               Zhuhai, Guangdong      \>420/\>360                          Rural         Coastal          2007         1112          164    14.75

  Cai \[[@B62]\]                2009               Hangzhou, Zhejiang     \>420/\>360                          Urban         Inland           2008         4155          702    16.90

  You \[[@B63]\]                2014               Mongolian              ≥416/≥357                            Urban         Inland           2009         630           120    19.05

  You \[[@B63]\]                2014               Mongolian              ≥416/≥357                            Rural         Coastal          2009         179           23     12.85

  Zhang \[[@B64]\]              2011               Tianjin                \>420/\>360                          Urban         Coastal          2009         17762         2160   12.16

                                                                                                                                                                                

  Prevalence of gout                                                                                                                                                            

  Yu \[[@B36]\]                 2010               Foshan, Guangdong      ---                                  Urban         Coastal          2008         7403          77     1.04

  Wu \[[@B37]\]                 2008               Guangzhou, Guangdong   ---                                  Urban         Inland           2007         2788          40     1.43

  Song \[[@B42]\]               2014               Nanchang, Jiangxi      ---                                  Urban         Inland           2011         3795          58     1.53

  Shao \[[@B43]\]               2003               Nanjing, Jiangsu       ---                                  Urban         Inland           2003         7778          105    1.35

  Zhang \[[@B49]\]              2006               Haiyang, Shandong      ---                                  Rural         Coastal          2004         5372          23     0.43

  Zhang \[[@B57]\]              2014               Xingtai, Hebei         ---                                  Rural         Inland           2013         2109          26     1.23
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Gout classification criteria.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Yu et al. \[[@B36]\]                                                               Wu et al., Song et al., Shao et al., Zhang et al., and Zhang et al. \[[@B37], [@B42], [@B43], [@B49], [@B57]\]
  ---------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
  Classification criteria for gout \[[@B25]\]\                                       ARA preliminary classification criteria for acute gout 1977 \[[@B24]\]\
  (1) More than one attack of acute arthritis\                                       (1) More than one attack of acute arthritis\
  (2) Maximum inflammation developed within 1 day\                                   (2) Maximum inflammation developed within 1 day\
  (3) Oligoarthritis attack\                                                         (3) Oligoarthritis attack\
  (4) Redness observed over joints\                                                  (4) Redness observed over joints\
  (5) First MTP joint painful or swollen\                                            (5) First MTP joint painful or swollen\
  (6) Unilateral first MTP joint attack\                                             (6) Unilateral first MTP joint attack\
  (7) Unilateral tarsal joint attack\                                                (7) Unilateral tarsal joint attack\
  (8) Tophus (suspected or proven)\                                                  (8) Tophus (suspected or proven)\
  (9) Hyperuricemia (more than 2 S.D. greater than the normal population average)\   (9) Hyperuricemia (more than 2 S.D. greater than the normal population average)\
  (10) Asymmetric swelling within a joint on X-ray\                                  (10) Asymmetric swelling within a joint on X-ray\
  (11) Complete termination of an attack\                                            (11) Subcortical cysts without erosions on X-ray\
  Case definition: ≥6 of 11 clinical criteria                                        (12) Complete termination of an attack\
                                                                                     Case definition: ≥6 of 12 clinical criteria required or presence of MSU crystals in SF or in tophus.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Stratified prevalence of hyperuricemia in mainland China.

  Subgroups        Prevalence (%) (95% CI)   Number of studies   Heterogeneity   Case/total   
  ---------------- ------------------------- ------------------- --------------- ------------ --------------
  Area                                                                                         
   Urban           13.7 (12.0, 15.4)         27                  98.4            \<0.001      14322/101787
   Rural           12.3 (10.5, 14.1)         11                  94.3            \<0.001      3154/24581
  Coastal/inland                                                                               
   Inland          13.8 (11.8, 15.7)         23                  98.3            \<0.001      10160/68666
   Coast           12.5 (10.8, 14.2)         15                  97.3            \<0.001      7316/57702
  Location                                                                                     
   North China     13.2 (11.5, 14.8)         13                  96.3            \<0.001      6162/48261
   East China      12.9 (10.2, 15.6)         12                  98.6            \<0.001      5577/40857
   Northwest       10.3 (5.4, 15.3)          3                   97.4            \<0.001      593/5382
   Northeast       10.1 (8.9, 11.2)          3                   0.0             0.376        275/2720
   Southwest       13.9 (11.7, 16.1)         3                   88.6            \<0.001      1533/11572
   South China     18.6 (13.8, 23.3)         4                   98.3            \<0.006      3336/17576
  Economic level                                                                               
   High            13.8 (12.0, 15.6)         20                  98.0            \<0.001      8094/59811
   Low             12.6 (10.6, 14.7)         18                  98.1            \<0.001      9382/66557
  Sex                                                                                          
   Male            19.4 (17.6, 21.1)         38                  96.7            \<0.001      11644/60768
   Female          7.9 (6.6, 9.3)            38                  97.9            \<0.001      5859/65654
  Total            13.3 (11.9, 14.6)         38                  98.0            \<0.001      17476/126368

###### 

Prevalence of gout in mainland China by different stratification factors.

  Subgroups         Prevalence (%)  (95% CI)   Number of studies   Heterogeneity   Case/total   
  ----------------- -------------------------- ------------------- --------------- ------------ -----------
  Area                                                                                           
   Urban            1.2 (0.7, 1.8)             4                   0.0             0.830        280/21764
   Rural            0.9 (0.2, 1.6)             2                   14.0            0.313        49/7481
   Coastal/inland                                                                                
   Inland           1.4 (0.8, 1.9)             4                   0.0             0.989        229/16470
   Coastal          0.8 (0.2, 1.4)             2                   0.4             0.316        100/12775
  Study year                                                                                     
   2000--2005       0.9 (0.0, 1.8)             2                   59.1            0.118        128/13150
   2006--2010       1.1 (0.4, 1.8)             2                   0.0             0.655        117/10191
   2011--2014       1.4 (0.5, 2.2)             2                   0.0             0.737        84/5904
  Sex                                                                                            
   Male             1.5 (0.8, 2.1)             6                   1.9             0.404        226/14060
   Female           0.9 (0.0, 1)               6                   0.0             0.924        78/15185
  Total             1.1 (0.7, 1.5)             6                   0.0             0.644        329/29245

[^1]: Academic Editor: Lorenzo Cavagna
